Ethnic differences in distributions of allelic and genotypic frequencies of NAT2 polymorphic variants in patients with pulmonary tuberculosis
N. M. Krasnova,
A. I. Fedorov,
O. A. Suvorova,
A. F. Kravchenko,
N. E. Evdokimova,
E. N. Efremova,
Ya. V. Hertovskykh,
E. A. Alekseeva,
Z. A. Rudykh,
O. L. Vasilieva,
D. A. Sychev https://doi.org/10.25789/YMJ.2019.68.05
Abstract
Ethnic differences in allele frequencies and genotype distribution for polymorphic variants of NAT2 gene (NAT2*5, NAT2*6, NAT2*7) were studied among ethnic Yakuts and Russians with newly diagnosed pulmonary tuberculosis. This is the first study to establish allele and genotype frequencies for polymorphic variants of NAT2 gene (NAT2*5, *6, *7) among ethnic Yakuts and Russians, who permanently reside in the Sakha Republic (Yakutia). Prevalence of NAT2*5, *6, *7 polymorphisms among Yakuts and Russians was determined, and ethnic differences were shown in allele frequencies and genotype distribution of NAT2 polymorphic variants: rs1801280 (341T>C), rs1799930 (590G>A), and rs1799931 (857G>A).
About the Authors
N. M. Krasnova
Medical Institute, M.K. Ammosov NorthEastern Federal University
Russian Federation
Russian Federation
Cand.Sci. (Medicine), associate professor of the Department for hospital therapy, clinical pharmacology and occupational diseases
Yakutsk, Republic Sakha (Yakutia)
A. I. Fedorov
Medical Institute, M.K. Ammosov NorthEastern Federal University
Russian Federation
Russian Federation
Cand.Sci. (Biology), senior researcher, Research center, Medical Institute
associate professor of the Department for public health and health care, general hygiene, and bioethics
Yakutsk, Republic Sakha (Yakutia)
O. A. Suvorova
I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
A. F. Kravchenko
Phtisiatry ResearchPractice Center
Russian Federation
Russian Federation
Dr.Sci. (Medicine), Director
N. E. Evdokimova
Phtisiatry Research-Practice Center
Russian Federation
Russian Federation
TB clinician
E. N. Efremova
Phtisiatry Research Practice Center
Russian Federation
Russian Federation
TB clinician, Pulmonary tuberculosis department
Ya. V. Hertovskykh
Republican Hospital No.3
Russian Federation
Russian Federation
Chief non-staff clinical pharmacologist of the Ministry of Health of the Sakha Republic (Yakutia), Head of the Center for Personalized Medicine
E. A. Alekseeva
Republican Hospital No.3
Russian Federation
Russian Federation
biologist, Genetic laboratory, Center for Personalized Medicine
Z. A. Rudykh
Republican Hospital No.3
Russian Federation
Russian Federation
clinical pharmacologist, Center for Personalized Medicine
O. L. Vasilieva
Republican Hospital No.3
Russian Federation
Russian Federation
Clinical pharmacologist, Center for Personalized Medicine
Moscow
D. A. Sychev
Russian Medical Academy of Continuous Professional Education
Russian Federation
Russian Federation
Dr.Sci.(Medicine), Prof., Corresponding Member of the Russian Academy of Sciences, Professor of the Russian Academy of Sciences, Principal
References
1. Variability of N-acetyltransferase phenotype in the citizens of Gomel and Gomel region / T.V. Satyrova, E.I. Mihailova, A.N. Osipenko [et al.] // Problems of health and ecology. -2010. -№1 (23). – P.73-77.
2. Kazakov R.E. Pharmacogenetics and clinical studies: common ground / R.E. Kazakov, N.G. Berdnikova, D.A. Sychev //Pharmacogenetics & pharmacogenomics. – 2016. – № 1. – P. 18–23.
3. Unfavorable side effects to first line anti-tuberculosis drugs / N.A. Stepanova [et al.] //Tuberculosis and Lung Diseases. – 2016. – V. 94. – № 5. – P. 42–45.
4. Federal Research Institute for Health Organization and Informatics of Ministry of Health of the Russian Federation. Indicators for tuberculosis in Russian Federation 2008-2017. URL: https://mednet.ru/images/materials/CMT/2018_god_tuberkulez_epidsituaciya.pdf. (accessed 8 June 2019).
5. Arylamine N-Acetyltransferase 2 (NAT2) Genetic Diversity and Traditional Subsistence: A Worldwide Population Survey / A. Sabbagh [et al.] // PLoS One. – 2011. – Vol.4, № 6. Available from:https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0018507 (accessed 20 June 2019). doi.org/10.1371/journal.pone.0018507.
6. Association and clinical utility of NAT2 in the prediction of isoniazid-induced liver injury in Singaporean patients / SL. Chan [et al.] // PLoS One. – 2017. – Vol. 12, № 10. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5642896/pdf/pone.0186200.pdf (accessed 20 June 2019). doi: 10.1371/journal.pone.0186200.
7. Correlation of N-Acetyltransferase 2 Genotype with Isoniazid Acetylation in Polish Tuberculosis Patients / J. Jagodziński [et al.] // Biomed Res. Int. – 2013. Available from: https://www.ncbi.nlm.nih.gov/pubmed/24383060 (accessed 6 June 2019) doi: 10.1155/2013/853602.
8. Determining the relation between N-acetyltransferase-2 acetylator phenotype and antituberculosis drug induced hepatitis by molecular biologic tests / V. BozokCetintaş [et al.] // TuberkToraks. – 2008. – Vol. 56, № 1. – P. 81–86.
9. Genetic polymorphisms of drug-metabolizing enzymes and anti-TB drug-induced hepatitis / SH. Kim [et al.] // Pharmacogenomics. – 2009. – Vol. 10, № 11. – P. 1767–1779. doi: 10.2217/pgs.09.100.
10. Genetic structure, self-identified race/ethnicity, and confounding in case-control association studies/ H. Tang [et al.] // Am J Hum Genet. – 2005. – Vol. 76, № 2. – P. 268–275.
11. Hein D. W. N-acetyltransferase 2 genetic polymorphism : effects of carcinogen and haplotype on urinary bladder cancer risk / D. W. Hein // Oncogene. – 2006. – Vol. 25, № 11. – P.1649–1658.
12. Jarrar YB. Sequence analysis of the N-acetyltransferase 2 gene (NAT2) among Jordanian volunteers / YB Jarrar, AA Balasmeh, W Jarrar // Libyan J Med. – 2018 – Vol. 13, № 1. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5717714/–1408381 (accessed 1 June 2019). doi: 10.1080/19932820.2017.1408381.
13. Kurose K. Population differences in major functional polymorphisms of pharmacokinetics / pharmacodynamics-related genes in Eastern Asians and Europeans: implications in the clinical trials for novel drug development / K. Kurose, E. Sugiyama, Y. Saito // Drug MetabPharmacokinet. – 2012. – Vol. 27, №1. – P. 9–54.
14. Low N-acetyltransferase 2 activity in isoniazid-associated acute hepatitis requiring liver transplantation / JP. Cramer [et al.] // Transpl Int. – 2010. – Vol. 23, № 2. – P. 231–233. doi: 10.1111/j.1432-2277.2009.00921.x.
15. Ma Q. Pharmacogenetics, pharmacogenomics, and individualized medicine / Q Ma, A.Y. Lu // Pharmacol Rev. – 2011. – Vol. 63, № 2. – P. 437–459. doi: 10.1124/pr.110.003533
16. Microarray-based detection of CYP1A1, CYP2C9, CYP2C19, CYP2D6, GSTT1, GSTM1,MTHFR,MTRR, NQO1,NAT2, HLADQA-1,and AB0 allele frequencies in native Russians / O. Gra [et al.] // Genet Test Mol Biomarkers. – 2010. – Vol. 14, № 3. – P. 329–342. doi: 10.1089/gtmb.2009.0158.
17. NAT2 and CYP2E1 polymorphisms associated with antituberculosis drug-induced hepatotoxicity in Chinese patients / HR. An [et al.] // Clin Exp Pharmacol Physiol. – 2012. – Vol. 39, № 6. – P. 535–543. doi: 10.1111/j.1440-1681.2012.05713.x.
18. NAT2 Gene Polymorphisms in Turkish Patients with Psoriasis Vulgaris / R. Dursun [et al.] //Biomed Res Int. – 2018. Available from: https://www.ncbi.nlm.nih.gov/pubmed/?term=NAT2+Gene+Polymorphisms+in+Turkish+Patients+with+Psoriasis+Vulgaris (accessed 15 June 2019) doi: 10.1155/2018/3258708.
19. Pharmacogenomics Knowledge for Personalized Medicine / Whirl-Carrillo [et al.] // Clinical Pharmacology & Therapeutics. – 2012. – Vol. 92, № 4. – P. 414–417. doi: 10.1038/clpt.2012.96
20. PharmGKB Summary: Isoniazid Pathway, Pharmacokinetics / Daniel J. Klein [et al.] // Pharmacogenet Genomics. – 2016. – Vol. 26, № 9. – P. 436–444. doi: 10.1097/FPC.0000000000000232
21. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatotoxicity in Tunisian patients with tuberculosis / L Ben Mahmoud [et al.] // PatholBiol (Paris). – 2012. – Vol. 60, № 5. – P. 324–330. doi: 10.1016/j.patbio.2011.07.001.
22. The Pharmacogenetics of NAT2 Enzyme Maturation in Perinatally HIV Exposed Infants Receiving Isoniazid / R. Zhu [et al.] // J Clin Pharmacol. – 2009. – Vol. 6, №11. – P. 1249–1254.
23. Tuberculosis Pharmacogenetics: State of The Art (March 20th 2013) / Raquel Lima de Figueiredo Teixeira [et al.] // Tuberculosis - Current Issues in Diagnosis and Management Available from: https://www.intechopen.com/books/tuberculosis-current-issues-in-diagnosis-and-management/tuberculosis-pharmacogenetics-state-of-the-art (accessed 5 June 2019). doi: 10.5772/54984.
Review
For citations:
Krasnova N.M., Fedorov A.I., Suvorova O.A., Kravchenko A.F., Evdokimova N.E., Efremova E.N., Hertovskykh Ya.V., Alekseeva E.A., Rudykh Z.A., Vasilieva O.L., Sychev D.A. Ethnic differences in distributions of allelic and genotypic frequencies of NAT2 polymorphic variants in patients with pulmonary tuberculosis. Yakut Medical Journal. 2019;(4):22-25. https://doi.org/10.25789/YMJ.2019.68.05
Views:
10
Email this article 